Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

ClinicalTrials.gov ID: NCT00615056

Public ClinicalTrials.gov record NCT00615056. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen

Study identification

NCT ID
NCT00615056
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
171 participants

Conditions and interventions

Interventions

  • AG-013736 (axitinib) Drug
  • Bevacizumab (avastin) Drug
  • FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) Drug
  • FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2008
Primary completion
Feb 28, 2011
Completion
Mar 31, 2012
Last update posted
Apr 18, 2013

2008 – 2012

United States locations

U.S. sites
61
U.S. states
13
U.S. cities
42
Facility City State ZIP Site status
Pfizer Investigational Site Mobile Alabama 36608
Pfizer Investigational Site Antioch California 94531
Pfizer Investigational Site Los Angeles California 90095-6984
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Pleasant Hill California 94523
Pfizer Investigational Site San Leandro California 94578
Pfizer Investigational Site Santa Monica California 90404
Pfizer Investigational Site Aurora Colorado 80045
Pfizer Investigational Site Bonita Springs Florida 34135
Pfizer Investigational Site Bradenton Florida 34209
Pfizer Investigational Site Cape Coral Florida 33914
Pfizer Investigational Site Cape Coral Florida 33990
Pfizer Investigational Site Englewood Florida 34223
Pfizer Investigational Site Fort Myers Florida 33901-8108
Pfizer Investigational Site Fort Myers Florida 33905
Pfizer Investigational Site Fort Myers Florida 33908
Pfizer Investigational Site Fort Myers Florida 33916
Pfizer Investigational Site Naples Florida 34102
Pfizer Investigational Site Naples Florida 34119
Pfizer Investigational Site Port Charlotte Florida 33980
Pfizer Investigational Site Sarasota Florida 34232
Pfizer Investigational Site Sarasota Florida 34236
Pfizer Investigational Site Venice Florida 34285
Pfizer Investigational Site Venice Florida 34292
Pfizer Investigational Site Atlanta Georgia 30318
Pfizer Investigational Site Ringgold Georgia 30736
Pfizer Investigational Site Dubuque Iowa 52001
Pfizer Investigational Site Crestview Hills Kentucky 41017
Pfizer Investigational Site Paducah Kentucky 42002
Pfizer Investigational Site Paducah Kentucky 42003
Pfizer Investigational Site Baltimore Maryland 21237
Pfizer Investigational Site New Albany Mississippi 38652
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cincinnati Ohio 45230
Pfizer Investigational Site Cincinnati Ohio 45236
Pfizer Investigational Site Cincinnati Ohio 45238
Pfizer Investigational Site Cincinnati Ohio 45242
Pfizer Investigational Site Cincinnati Ohio 45248
Pfizer Investigational Site Fairfield Ohio 45014
Pfizer Investigational Site Hamilton Ohio 45013
Pfizer Investigational Site Chattanooga Tennessee 37404
Pfizer Investigational Site Franklin Tennessee 37067
Pfizer Investigational Site Gallatin Tennessee 37066
Pfizer Investigational Site Germantown Tennessee 38138
Pfizer Investigational Site Hermitage Tennessee 37076
Pfizer Investigational Site Hixson Tennessee 37343
Pfizer Investigational Site Lebanon Tennessee 37087
Pfizer Investigational Site Murfreesboro Tennessee 37130
Pfizer Investigational Site Nashville Tennessee 37203
Pfizer Investigational Site Nashville Tennessee 37205
Pfizer Investigational Site Nashville Tennessee 37207
Pfizer Investigational Site Nashville Tennessee 37211
Pfizer Investigational Site Nashville Tennessee 37232
Pfizer Investigational Site Paris Tennessee 38242
Pfizer Investigational Site Smyrna Tennessee 37167
Pfizer Investigational Site Union City Tennessee 38261
Pfizer Investigational Site Corpus Christi Texas 78463
Pfizer Investigational Site Mechanicsville Virginia 23116
Pfizer Investigational Site Midlothian Virginia 23114
Pfizer Investigational Site Richmond Virginia 23230
Pfizer Investigational Site Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00615056, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 18, 2013 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00615056 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →